KOTA KINABALU: As healthcare continues to evolve from conventional disease management towards prevention, cellular health and biological repair, regenerative medicine is emerging as one of the most promising areas of modern biomedical science.
BIOLIVE (M) Sdn. Bhd., a biotechnology-focused company committed to advancing awareness, innovation and responsible access to emerging health technologies.
Regenerative medicine represents a fundamentally different way of thinking about healthcare.
Rather than focusing solely on managing symptoms, the field explores ways to support the body’s natural repair and regeneration mechanisms, with research spanning stem cells, tissue engineering, extracellular vesicles and other advanced biological technologies.
According to BIOLIVE, the growing interest in regenerative medicine reflects a broader transformation in healthcare — from simply extending lifespan towards improving health span, quality of life and healthy ageing. From Treatment-Centred Healthcare to Regenerative Science.
For decades, modern medicine has achieved remarkable progress in diagnosing and treating disease.
However, as populations age and chronic and degenerative conditions become increasingly prevalent, researchers worldwide are exploring new approaches that may complement conventional healthcare. Regenerative medicine is one such frontier.
The field seeks to understand how biological systems repair themselves and how these natural mechanisms may potentially be supported or enhanced. Research in areas such as stem cell biology, tissue engineering and extracellular vesicles is continuing to expand globally.
BIOLIVE’s Commitment to Scientific Dialogue BIOLIVE believes that the development of regenerative medicine should be accompanied by scientific education, professional dialogue and responsible communication.
In 2026, the company organised a series of scientific seminars bringing together medical professionals, researchers and international experts to discuss regenerative medicine, stem cell research, tissue engineering, healthy ageing and ocular health.
Among the speakers and experts participating in BIOLIVE’s scientific programmes have been Tan Sri Dato’ Seri Dr. Noor Hisham Abdullah, former Director-General of Health Malaysia; Assoc. Prof. Dr. Angela Ng Min Hwei from the Department of Tissue Engineering and Regenerative Medicine at Universiti Kebangsaan Malaysia Medical Centre; Dato’ Dr. Jaswant Singh, clinical consultant oncologist; Prof. Dr. Su Yung Tsun, Director of the Taiwan Anti-aging Medical Association; and other specialists from Malaysia and Taiwan.
These programmes are designed to create a platform for knowledge exchange and to help the public better understand both the potential and the current limitations of regenerative medicine.
Building a Bridge Between Biotechnology and Everyday Health BIOLIVE’s biotechnology portfolio reflects its broader interest in cellular health, healthy ageing, immunity and emerging health technologies. Its flagship product, RiboN, is positioned by BIOLIVE as part of its healthy-ageing and cellular-health portfolio.
BIOLIVE emphasises that nutritional products and regenerative medicine therapies are distinct categories and should not be confused.
While scientific research may explore biological mechanisms associated with cellular health and regeneration, product claims must remain consistent with their respective regulatory classifications and available scientific evidence.
This distinction is central to BIOLIVE’s approach: innovation must move together with scientific responsibility and regulatory compliance.
Expanding into Ocular Regenerative Science BIOLIVE has also expanded its scientific focus into ocular health, reflecting the growing interest in regenerative approaches for tissues and organs affected by ageing and degeneration.
At an August 2026 scientific seminar in Kota Kinabalu, experts discussed stem cells, induced pluripotent stem cells, extracellular vesicles and the emerging science of ocular regeneration. The programme also introduced BIOLIVE’s i-RE & e-RE eye-health product line.
The discussion highlighted the potential of regenerative science while recognising that many applications remain under active research and clinical evaluation.
A New Era of Healthcare “Regenerative medicine represents a significant shift in how we think about the future of healthcare,” said a BIOLIVE spokesperson.
“It is not simply about developing another product. It is about understanding the body’s own biological mechanisms, supporting scientific discovery and creating new possibilities for healthier ageing and improved quality of life.”
BIOLIVE believes that the future of healthcare will increasingly involve collaboration between medical science, biotechnology, nutrition, research institutions and healthcare professionals.
The company’s vision is to contribute to this development by creating platforms for scientific exchange, supporting biotechnology innovation and promoting greater public understanding of emerging healthcare technologies.
As regenerative medicine continues to develop, BIOLIVE remains committed to a simple principle: Science first. Innovation with responsibility. Better health for the future.-pr/BNN
